Coeptis Therapeutics (NASDAQ:COEP) Stock Price Up 2.8% – What’s Next?
by Doug Wharley · The Cerbat GemCoeptis Therapeutics Holdings, Inc. (NASDAQ:COEP – Get Free Report)’s share price rose 2.8% during trading on Tuesday . The company traded as high as $12.44 and last traded at $12.44. Approximately 23,743 shares changed hands during trading, a decline of 53% from the average daily volume of 50,972 shares. The stock had previously closed at $12.10.
Analyst Ratings Changes
Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Coeptis Therapeutics in a research note on Wednesday, January 21st. One research analyst has rated the stock with a Sell rating, According to MarketBeat.com, Coeptis Therapeutics presently has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on Coeptis Therapeutics
Coeptis Therapeutics Stock Performance
The stock has a 50 day simple moving average of $11.78 and a 200 day simple moving average of $13.99. The company has a current ratio of 4.16, a quick ratio of 4.16 and a debt-to-equity ratio of 0.01. The stock has a market cap of $77.38 million, a P/E ratio of -4.17 and a beta of -0.44.
Coeptis Therapeutics (NASDAQ:COEP – Get Free Report) last issued its quarterly earnings results on Thursday, March 19th. The company reported ($0.12) earnings per share (EPS) for the quarter. Coeptis Therapeutics had a negative net margin of 803.96% and a negative return on equity of 110.89%. The business had revenue of $0.86 million during the quarter.
Hedge Funds Weigh In On Coeptis Therapeutics
Several hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its stake in shares of Coeptis Therapeutics by 12.6% in the 4th quarter. Geode Capital Management LLC now owns 42,097 shares of the company’s stock valued at $600,000 after purchasing an additional 4,721 shares during the last quarter. State Street Corp increased its stake in shares of Coeptis Therapeutics by 35.0% in the 4th quarter. State Street Corp now owns 26,830 shares of the company’s stock valued at $382,000 after purchasing an additional 6,962 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Coeptis Therapeutics in the 4th quarter valued at $259,000. Yorkville Advisors Global LP bought a new position in shares of Coeptis Therapeutics in the 3rd quarter valued at $140,000. Finally, Steward Partners Investment Advisory LLC increased its stake in shares of Coeptis Therapeutics by 100.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 5,000 shares of the company’s stock valued at $71,000 after purchasing an additional 2,500 shares during the last quarter. Institutional investors own 13.88% of the company’s stock.
Coeptis Therapeutics Company Profile
Coeptis Therapeutics Holdings, Inc, a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy.